{element.icon}: Otfried-Müller-Str. 10, 72076 Tübingen{element.icon}: Auf der Morgenstelle 15, 72076 Tübingen

Office:{element.icon}: +49 7071 29-82834{element.icon}: +49 7071 29-4391{element.icon}:


T cell-based immunity not only plays an important role in tumor diseases, but is also crucial for the defense against viral infections. During the COVID-19 pandemic, we decided to leverage our experience and expertise in tumor immunology to contribute to this field as well. After pioneering preclinical contributions to the understanding of the SARS-CoV-2 T cell response, we developed the T cell activator CoVac-1 with the goal of inducing a protective T cell response in tumor patients and other immunocompromised patients at high risk for a severe COVID-19 course. In a first phase I study in healthy volunteers, CoVac-1 was evaluated with highly encouraging data regarding safety and immunogenicity (NCT04546841). Based on this, CoVac-1 is currently being investigated in a phase II study in patients with congenital and acquired immunodeficiencies with the goal of providing effective protection against severe COVID-19 in this high-risk patient population in the future.